Type II diabetes cure may soon be available through stem cell therapy, reveals PGI study
- Supreme Court to hear plea today for relook at verdict on gay sex
- J&K Governor calls for talks today, PDP signals phone call from Delhi may bring back BJP alliance
- RBI keeps repo rate unchanged at 6.7%; CRR at 4%
- Raigad: 13 Pune college students drown during picnic at Murud beach
- Zika virus outbreak: WHO declares global emergency
A study conducted by the Department of Endocrinology's doctors has revealed the efficacy of the therapy, so much so that the patients injected with stem cells required 50 per cent less insulin as compared to those who were not administered the stem cells.
The study, sponsored by the Defence Research Development Organisation (DRDO), PGIMER used stem cells to treat a group of patients having Type II diabetes or metabolic disorder that is characterised by high blood glucose while another set of patients was given "placebo treatment" or dummy treatment.
"Eighty per cent of people benefited after stem cell treatment and this group of patients have been under regular follow-up for the past three years. The study showed that stem cells in one set of patients were actually working to maintain the blood sugar levels. These patients also emphatically showed improvement in functioning of their pancreas, said Dr Anil Bhansali, HOD.
Significantly, another set of patients who were given placebo treatment, wherein a patient feels he is being treated with medicines while actually he/she is not, also showed some reduction in insulin requirement. However, their improvement was very insignificant as compared to the other group and was not scientifically sustainable.
However, Dr Bhansali added that it will take years of research before the stem cell therapy is taken as a line of treatment for such patients. The cost of this treatment is Rs 20,000 per shot and the patient's own stem cells are derived and are injected back in the body.
Type 2 diabetes is characterised by two defects - insulin resistance and insulin deficiency. The former is fairly constant, with beta cell function progressively deteriorating and majority of patients finally being on insulin.
China is new diabetes capital
- Ten years on, MGNREGA requires constant review. And consistency in political support
- The global economy is in trouble but India is attracting positive comment
- India’s expanding stakes in US demand a more strategic view of their changing politics
- Supreme Court has an opportunity to rectify its ruling on Section 377
- And everyone loves censorship — or so it seemed, at a session at the Jaipur Lit Fest
- The problem in Arunachal is as much about politics as about institutional norms